' 
SCIENTIFIC SCORE
Most Likely Effective
Based on 7 Researches
7
USERS' SCORE
Excellent
Based on 2 Reviews
9.5
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Iron (from Ionic Plant Based Minerals)
2 mg
10%
HSO Probiotic Blend (5 Billion CFU)¹Saccharomyces boulardii, Organic Barley Grass², Organic Oat Grass², Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, Lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, Lactobacillus paracasei
410 mg
+
Ionic Plant Based Minerals
290 mg
+
Top Medical Research Studies
9
Iron treatment effects on heart
Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure.
Directly addresses the issue
We investigated the role of iron treatment in managing heart disease, particularly its isolated effects. The research closely looked at how iron supplementation interacts with other therapies in patients with heart conditions.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
Read More
7
Ferric carboxymaltose efficacy in heart failure
Rationale and design of the FAIR-HF2-DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure.
Highly relevant to heart disease
In our investigation, we focused on a critical question: Can ferric carboxymaltose (FCM), an intravenous iron treatment, improve outcomes for patients with heart failure who have iron deficiency? To explore this, we conducted an extensive trial involving over 1100 patients diagnosed with chronic heart failure and reduced ejection fraction. These individuals were already battling iron deficiency, marked by low levels of serum ferritin and transferrin saturation.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
Read More
7
Iron's role in heart failure
Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations.
Study highlights iron deficiency implications
We explored the relationship between iron levels and heart failure outcomes by analyzing data from 2050 participants with varying left ventricular ejection fractions. The study aimed to determine how serum iron, ferritin, and transferrin saturation (TSAT) affect the prognosis for individuals already diagnosed with heart failure.
Our findings revealed that low transferrin saturation is linked to more serious outcomes in heart failure patients, particularly those with preserved ejection fraction. Surprisingly, the traditional marker of iron deficiency, ferritin concentrations, did not correlate with adverse outcomes at all. This indicates that TSAT could be a more relevant measure for assessing risk in these patients than previously thought.
Interestingly, while low TSAT showed strong associations with risks like all-cause death and heart failure-related hospital admissions, established criteria for defining iron deficiency did not clearly indicate such risks. We also identified numerous proteins associated with TSAT, hinting at pathways involving inflammation and lipid metabolism that could influence heart health.
Overall, the study suggests that monitoring TSAT may provide important insights into the health risks associated with heart failure, regardless of whether patients meet current definitions of iron deficiency.
Our findings revealed that low transferrin saturation is linked to more serious outcomes in heart failure patients, particularly those with preserved ejection fraction. Surprisingly, the traditional marker of iron deficiency, ferritin concentrations, did not correlate with adverse outcomes at all. This indicates that TSAT could be a more relevant measure for assessing risk in these patients than previously thought.
Interestingly, while low TSAT showed strong associations with risks like all-cause death and heart failure-related hospital admissions, established criteria for defining iron deficiency did not clearly indicate such risks. We also identified numerous proteins associated with TSAT, hinting at pathways involving inflammation and lipid metabolism that could influence heart health.
Overall, the study suggests that monitoring TSAT may provide important insights into the health risks associated with heart failure, regardless of whether patients meet current definitions of iron deficiency.
Read More
Most Useful Reviews
9.5
Heart burn relief
Amazing! I have been meaning to write this review for months! I've had fantastic results using this product (Primal Defense Ultra). I suffered from severe heart burn for years and even developed an ulcer a couple of years ago. I took one capsule last Halloween, anticipating the usual discomfort from candy. To my delight, I felt near-instant relief. This product has provided what my gut needed! I highly recommend it to everyone! I haven't experienced heart burn since taking the first capsule!
Read More
9.5
Heart burn management
The best I have ever tried! I used to have issues with heart burn. This has been amazing!
Read More
Most Recommended Products for Heart Disease
Solaray Timed Release Vitamin C with Rose Hips & Acerola
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
NOW Foods Solutions
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
American Health Ester-C with Citrus Bioflavonoids
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 2 Reviews
9.2
Medical Researches
SCIENTIFIC SCORE
Most Likely Effective
Based on 7 Researches
7
9
Combination therapy for heart injury
Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models.
Combines iron chelation and treatment
We explored how iron impacts heart disease by developing a targeted delivery system that addresses myocardial ischemia-reperfusion injury (MIRI), a condition that leads to significant heart damage. This integrated system utilized cerium oxide (CeO) nanoparticles alongside dexrazoxane (DXZ), an iron-chelating agent, to improve therapeutic outcomes. By loading these components into mesoporous polydopamine nanoparticles, we aimed to enhance their delivery to the heart and specifically to the damaged mitochondria where they are most needed.
The results of our study were promising. We found that the combination of iron chelation and antioxidant properties significantly reduced oxidative stress and inhibited ferroptosis, a form of cell death linked to heart injury. Additionally, this approach led to improved cardiac function and reduced inflammation, which are crucial for recovery after MIRI.
Overall, this hierarchical targeting system offers a new avenue not only for the clinical use of DXZ but also for advancing nanomedicine interventions in heart repair. However, it’s important to note that while iron plays a role in this therapeutic approach, isolating its specific effects on heart disease remains challenging due to the combination with other treatment methods in our study.
The results of our study were promising. We found that the combination of iron chelation and antioxidant properties significantly reduced oxidative stress and inhibited ferroptosis, a form of cell death linked to heart injury. Additionally, this approach led to improved cardiac function and reduced inflammation, which are crucial for recovery after MIRI.
Overall, this hierarchical targeting system offers a new avenue not only for the clinical use of DXZ but also for advancing nanomedicine interventions in heart repair. However, it’s important to note that while iron plays a role in this therapeutic approach, isolating its specific effects on heart disease remains challenging due to the combination with other treatment methods in our study.
Read More
9
Iron treatment effects on heart
Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure.
Directly addresses the issue
We investigated the role of iron treatment in managing heart disease, particularly its isolated effects. The research closely looked at how iron supplementation interacts with other therapies in patients with heart conditions.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
Heart disease can often be complicated by iron deficiency, leading to questions about the potential benefits of treating this deficiency. Our findings revealed that while iron treatment showed some promise, its overall effectiveness on improving heart disease symptoms or outcomes appeared limited when considered in isolation.
Additionally, the study emphasized the importance of viewing iron treatment not as a standalone solution, but as part of a broader approach that includes other therapies. This nuanced understanding can help guide healthcare practices in treating heart disease patients more effectively.
Read More
7
Iron levels impact heart function
Left ventricular diastolic and systolic functions by cardiac magnetic resonance in beta-thalassemia major: correlation with clinical findings and cardiac complications.
Relevant correlation without isolation
We investigated how iron affects heart health in individuals with beta-thalassemia major (β-TM). In our study, we included 292 β-TM patients and 20 healthy individuals to compare their heart functions using cardiac magnetic resonance (CMR) technology.
Our findings revealed that iron overload in the heart is a significant concern for patients with β-TM. We found a strong correlation between high levels of myocardial iron overload (MIO) and lower heart function, evidenced by reduced left ventricular (LV) systolic indexes. This suggests that the more iron accumulated in the heart, the worse the heart's pumping ability tends to be.
While our analysis showed an association between iron levels and heart function, we did not find any significant improvement in heart function related to iron treatment itself in this population. Notably, the presence of late gadolinium enhancement (LGE), which indicates damage to the heart muscle, also appeared as a key factor affecting heart function in these patients.
Overall, while iron overload poses risks to heart health for β-TM patients, our study indicates that management of iron levels alone has not been proven to effectively improve heart function or prevent complications.
Our findings revealed that iron overload in the heart is a significant concern for patients with β-TM. We found a strong correlation between high levels of myocardial iron overload (MIO) and lower heart function, evidenced by reduced left ventricular (LV) systolic indexes. This suggests that the more iron accumulated in the heart, the worse the heart's pumping ability tends to be.
While our analysis showed an association between iron levels and heart function, we did not find any significant improvement in heart function related to iron treatment itself in this population. Notably, the presence of late gadolinium enhancement (LGE), which indicates damage to the heart muscle, also appeared as a key factor affecting heart function in these patients.
Overall, while iron overload poses risks to heart health for β-TM patients, our study indicates that management of iron levels alone has not been proven to effectively improve heart function or prevent complications.
Read More
7
Ferric carboxymaltose efficacy in heart failure
Rationale and design of the FAIR-HF2-DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure.
Highly relevant to heart disease
In our investigation, we focused on a critical question: Can ferric carboxymaltose (FCM), an intravenous iron treatment, improve outcomes for patients with heart failure who have iron deficiency? To explore this, we conducted an extensive trial involving over 1100 patients diagnosed with chronic heart failure and reduced ejection fraction. These individuals were already battling iron deficiency, marked by low levels of serum ferritin and transferrin saturation.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
The study was thoughtfully designed as a multicenter, randomized, double-blind trial. Patients were split into two groups—one receiving FCM and the other a placebo—allowing us to compare the effects of iron treatment robustly. Over a median follow-up of two years, we looked for key outcomes, including the time to cardiovascular death or hospitalizations related to heart failure.
While previous trials had shown that iron could benefit patients' functional capacity, our study takes this further by using higher doses of iron. The approach aims to prevent future iron deficiency after initial repletion. However, it’s essential to note that other recent trials have not demonstrated significant benefits with iron supplementation, raising important questions about how effective this treatment truly is in enhancing cardiovascular outcomes.
Ultimately, FAIR-HF2 could provide more clarity on whether aggressive iron supplementation can genuinely support patients with heart failure. If successful, this could transform how we manage heart disease for those struggling with iron deficiency, giving them a better chance at improved health outcomes.
Read More
7
Iron's role in heart failure
Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations.
Study highlights iron deficiency implications
We explored the relationship between iron levels and heart failure outcomes by analyzing data from 2050 participants with varying left ventricular ejection fractions. The study aimed to determine how serum iron, ferritin, and transferrin saturation (TSAT) affect the prognosis for individuals already diagnosed with heart failure.
Our findings revealed that low transferrin saturation is linked to more serious outcomes in heart failure patients, particularly those with preserved ejection fraction. Surprisingly, the traditional marker of iron deficiency, ferritin concentrations, did not correlate with adverse outcomes at all. This indicates that TSAT could be a more relevant measure for assessing risk in these patients than previously thought.
Interestingly, while low TSAT showed strong associations with risks like all-cause death and heart failure-related hospital admissions, established criteria for defining iron deficiency did not clearly indicate such risks. We also identified numerous proteins associated with TSAT, hinting at pathways involving inflammation and lipid metabolism that could influence heart health.
Overall, the study suggests that monitoring TSAT may provide important insights into the health risks associated with heart failure, regardless of whether patients meet current definitions of iron deficiency.
Our findings revealed that low transferrin saturation is linked to more serious outcomes in heart failure patients, particularly those with preserved ejection fraction. Surprisingly, the traditional marker of iron deficiency, ferritin concentrations, did not correlate with adverse outcomes at all. This indicates that TSAT could be a more relevant measure for assessing risk in these patients than previously thought.
Interestingly, while low TSAT showed strong associations with risks like all-cause death and heart failure-related hospital admissions, established criteria for defining iron deficiency did not clearly indicate such risks. We also identified numerous proteins associated with TSAT, hinting at pathways involving inflammation and lipid metabolism that could influence heart health.
Overall, the study suggests that monitoring TSAT may provide important insights into the health risks associated with heart failure, regardless of whether patients meet current definitions of iron deficiency.
Read More
User Reviews
USERS' SCORE
Excellent
Based on 2 Reviews
9.5
9.5
Heart burn relief
Amazing! I have been meaning to write this review for months! I've had fantastic results using this product (Primal Defense Ultra). I suffered from severe heart burn for years and even developed an ulcer a couple of years ago. I took one capsule last Halloween, anticipating the usual discomfort from candy. To my delight, I felt near-instant relief. This product has provided what my gut needed! I highly recommend it to everyone! I haven't experienced heart burn since taking the first capsule!
Read More
9.5
Heart burn management
The best I have ever tried! I used to have issues with heart burn. This has been amazing!
